Oculopharyngeal Muscular Dystrophy Stocks List
Related Industries: Drug Manufacturers - Specialty & Generic
Related Stock Lists:
Ai Technology
Biology
Biopharmaceutical
Biotechnology
Chemotherapy
Chronic And Life Threatening Conditions
Clinical Applications
Dystrophy
Gene Expression
Gene Silencing
Genetic Engineering
Genetics
HIV/Aids
Hepatitis B
Hepatitis C
Huntington's Disease
Macular Degeneration
Muscular Dystrophy
Pain
RNA
Related ETFs - A few ETFs which own one or more of the above listed Oculopharyngeal Muscular Dystrophy stocks.
Date | Stock | Title |
---|---|---|
Nov 14 | BNTC | Benitec GAAP EPS of -$0.48 |
Nov 14 | BNTC | Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update |
Related Industries:
Drug Manufacturers - Specialty & Generic
Related Stock Lists:
Ai Technology
Biology
Biopharmaceutical
Biotechnology
Chemotherapy
Chronic And Life Threatening Conditions
Clinical Applications
Dystrophy
Gene Expression
Gene Silencing
Genetic Engineering
Genetics
HIV/Aids
Hepatitis B
Hepatitis C
Huntington's Disease
Macular Degeneration
Muscular Dystrophy
Pain
RNA
- Oculopharyngeal Muscular Dystrophy
Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, inherited form of muscular dystrophy that affects the eyes, throat, and upper arms. It is characterized by progressive weakness and wasting of the muscles of the eyes, throat, and upper arms. Symptoms typically begin in adulthood and include drooping eyelids, difficulty swallowing, and weakness in the shoulder and arm muscles. OPMD is caused by a mutation in the PABPN1 gene. Treatment is focused on managing symptoms and may include physical therapy, speech therapy, and medications.
Recent Comments
- TraderMike on BOOT
- Dr_Duru on BOOT
- TraderMike on Stochastic Reached Oversold
- SuccessfulGrasshopper897 on Stochastic Reached Oversold
- Cos3 on Adding float as advanced filter criteria?
From the Blog
Featured Articles